BRAF and melanoma: In a phase 3 trial, median PFS was 12.3 months for cobimetinib plus vemurafenib versus 7.2 months for vemurafenib alone, and these data supported the use of combination as a standard first-line approach to improve survival in patients with advanced BRAF V600-mutant melanoma [43].